Menu
Curie Logo
Donate
  • Home

Clinical trials - page 4

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Saint-Cloud
    EPIC 1511
    Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial.

    ELISABETH LUCCHI

  • Saint-Cloud
    EPITOP 01
    Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial

    MICHAEL BRINGUIER

  • Saint-Cloud
    ER-One (IC 2020-04)
    A Double-blind Randomized Non-inferiority Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery: Effects on Acute Postoperative Pain.

    ALINE ALBI-FELDZER

  • Lung cancer
    Paris
    EVOKE-SCLC-04 - (GS-US-600-6165)
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04).

    NICOLAS GIRARD

  • Saint-Cloud
    Epi R-CHOP
    A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP

    CLEMENTINE SARKOZY

  • Breast cancer
    Paris
    EvoPAR-Breast01
    A Randomised, Open-Label, Phase III Study of AZD5305 Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of BRCA1, BRCA2, or PALB2-mutated Patients with Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer ().

    DELPHINE LOIRAT

  • Saint-Cloud
    FAST
    French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study

    SANDRA MALAK

  • Saint-Cloud
    FIGARO
    Feasibility and Accuracy of Lymph-node (LN) Restaging by Sentinel LN Procedure and Axillary LN Dissection in Ipsilateral Invasive Breast Cancer Relapse

  • Saint-Cloud
    FORWARD-1
    FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

    ANNE DONNADIEU

  • Breast cancer
    Paris, Saint-Cloud
    Flamingo-01
    A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01).

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    GANEA 3
    Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma.

    EUGENIE GUILLOT

  • Saint-Cloud
    GATA
    A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas

    CAROLE SOUSSAIN

  • Kidney cancer
    Paris
    GETUG-StORM-01
    A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases.

  • Lymphoma
    Saint-Cloud
    GO43878(GLOBRYTE)
    A PHASE III, OPEN-LABEL, MULTICENTER,;RANDOMIZED STUDY EVALUATING GLOFITAMAB AS;A SINGLE AGENT VERSUS INVESTIGATORÀS CHOICE;IN PATIENTS WITH RELAPSED/REFRACTORY;MANTLE CELL LYMPHOMA.

    CLEMENTINE SARKOZY

  • Cervical cancer
    Saint-Cloud
    GYNET
    A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.

    DIANA BELLO ROUFAI

  • Breast cancer
    Paris, Saint-Cloud
    HEROES
    De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

    DIANA BELLO ROUFAI

  • Childhood and adolescent cancers
    Paris
    HR-NBL2
    High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

    GUDRUN SCHLEIERMACHER

  • Saint-Cloud
    IMMUNO-BIL (D48-1 PRODIGE 57)
    Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study

  • Thymic tumors
    Paris
    IMMUNO-TET
    Characterisation of the immune infiltrate and molecular features of Thymic Epithelial Tumours (TETs).

    CLEMENCE BASSE

  • Thyroid cancer
    Saint-Cloud
    INTERMEDIATE-01
    Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy

    CAPUCINE RICHARD

  • Saint-Cloud
    IONESCO (IFCT-1601)
    A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer.

    MARIE ANGE MASSIANI

  • Saint-Cloud
    IROCAS - PRODIGE 52
    A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting

  • Paris
    LCB-1801-001
    A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS.

    EMANUELA ROMANO

  • Lung cancer
    Paris
    Lunar- 2
    LUNAR-2: a pivotal, randomized, open-label trial of Tumor Treating Fields (TTFields, 150 kHz) combined with pembrolizumab and platinum-based chemotherapy in the treatment of metastatic non·small cell lung cancer.

    NICOLAS GIRARD

  • Saint-Cloud
    M20-621
    A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    MAPAM-01
    Therapeutic Nipple Areola Skin-sparing Mastectomy.

    EUGENIE GUILLOT

  • Saint-Cloud
    MCLA-128-CL01
    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  • Saint-Cloud
    MCLA-128-CL02
    Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

    FRANCOIS-CLEMENT BIDARD

  • Paris
    MCLA-158-CL01
    Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

    EDITH BORCOMAN

  • Thyroid cancer
    Saint-Cloud
    MIBI-THYR
    Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.

    CAPUCINE RICHARD

<
1 ...4...7
>